CAS: 884494-76-2; 6-Chloro-3-Fluoropicolinic Acid

相似化合物

884494-77-3 1207609-52-6 1214363-79-7

上下游产品

6-chloro-3-fluoro-2-methylpyridine 6-chloro-4-methyl-3-nitropyridine methyl 6-chloro-3-fluoropyridine-2-carboxylate

2-氯-5-氟-6-甲基吡啶置于potassium Dichromate,Sodium Tungstate (Vi) Dihydrate,18-冠醚-6,硫酸体系中,化学反应 6.0H,以93.5%的收率获得产物2-氯-5-氟吡啶-6-羧酸
参考文献:6-氯-3-氟-2-吡啶甲酸的合成
标题:6-氯-3-氟-2-吡啶甲酸的合成
摘要:本发明公开了一种6-氯-3-氟-2-吡啶甲酸的合成工艺,所采用的主要起始原料为6-氯-3-氟-2-甲基吡啶.以6-氯-3-氟-2-甲基吡啶为起始原料,稀硫酸作为反应溶剂,重铬酸钾为氧化剂,钨酸钠(na2Wo4.2H2O)及冠醚为组合催化剂,反应完全后,通过常规后处理得到粗品,加热将该粗品溶解于碱性水溶液,用有机溶剂萃取未反应的微量原料及其它杂质,水层用无机酸酸化,冷却结晶,得到6-氯-3-氟-2-吡啶甲酸纯品,收率高,产品品质好.

专利信息

专利号:CN-104003934-A
优先权日:2014-06-13
标题 :Synthesis of 6-chloro-3-fluoro-2-pyridinecarboxylic acid

专利号:CN-104003934-B
优先权日:2014-06-13
标题:Synthesis of 6-chloro-3-fluoro-2-pyridinecarboxylic acid

专利号:WO-2012131037-A1
优先权日:2011-03-31
标 题 :Radiolabelled flumazenil derivatives
发明人：SOLBAKKEN MAGNE; GAETA ALESSANDRA; O'SHEA DENNIS; JACKSON ALEXANDER; TRIGG WILLIAM JOHN
权利人:GE HEALTHCARE LTD; SOLBAKKEN MAGNE; GAETA ALESSANDRA; O'SHEA DENNIS; JACKSON ALEXANDER; TRIGG WILLIAM JOHN
摘要:A novel 18F- labelled compound suitable for use as a PET tracer for imaging GABA receptors is provided as well as a precursor compound for use in its synthesis and methods for its preparation. Also disclosed herein is an in vivo imaging method comprising administration of said 18F- labelled compound, which finds use in the diagnosis of conditions in which expression of the GABAA receptor is abnormal, or in the monitoring of such conditions.

专利号:US-9856241-B2
优先权日:2013-07-03
标 题:Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
发明人：BALOGLU ERKAN; SHACHAM SHARON; SENAPEDIS WILLIAM; MCCAULEY DILARA; LANDESMAN YOSEF; GOLAN GALI; KALID ORI; SHECHTER SHARON
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of Structural Formula (A), or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of cancer (e.g., mantle cell lymphoma), and other diseases and disorders.